更新于：2024-06-22
EGb-761
更新于：2024-06-22
概要
基本信息
在研机构 |
最高研发阶段批准上市 |
首次获批日期 法国 (2002-02-28), |
最高研发阶段(中国)- |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C11H13ClN2S |
InChIKeyLAZPBGZRMVRFKY-HNCPQSOCSA-N |
CAS号16595-80-5 |
关联
16
项与 EGb-761 相关的临床试验An Observational, Open Label, Post Marketing Study to Evaluate the Safety and Effectiveness of Hoat Huyet Nhat Nhat Compared With Gingko Biloba EGb761 (Tanakan 40mg) in Patients With Symptoms Related to the Insufficient Blood Supply to the Brain
Non-interventional Prospective Observational Study to Describe EGB 761® (Tanakan®) Effectiveness in the Treatment of Patients of Middle Age and Younger With Psycho-emotional Symptoms, Added to Cognitive Disorders.
Randomized, open-label, parallel-group study to assess the feasibility of patient selection, treatment regimen and outcome measures and to obtain preliminary data for sample size estimation for a trial to evaluate treatment effects on cognitive and emotional functioning of Ginkgo biloba extract EGb 761® in patients who had suffered an acute ischemic stroke
100 项与 EGb-761 相关的临床结果
登录后查看更多信息
100 项与 EGb-761 相关的转化医学
登录后查看更多信息
100 项与 EGb-761 相关的专利（医药）
登录后查看更多信息
938
项与 EGb-761 相关的文献（医药）2023-12-01Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS)
Enhanced expression of RAGE/NADPH oxidase signaling pathway and increased level of oxidative stress in brains of rats with chronic fluorosis and the protective effects of blockers
Article
作者: Ma, Yan-Lin ; Zhang, Kai-Lin ; Zhang, Ting ; Deng, Jie ; Liang, Qiu-Zhe ; Li, Hong-Mei
This investigation was designed to examine the potential involvement of RAGE/NADPH oxidase signaling in the damage to the brain caused by chronic fluorosis. Sprague-Dawley rats were divided randomly into 9 groups each containing 20 animals, Controls (C); rats receiving low (i.e., 10 ppm) (LF) or high does ( i.e., 50 ppm) (HF) of fluoride in their drinking water; and these same groups injected with FPS-ZM1, an inhibitor of RAGE, (CF, LFF and HFF, respectively) or administered EGb761, an active ingredient of Ginkgo biloba extract, intragastrically (CE, LFE, and HFE). Following 3 and 6 months of such treatment, the spatial learning and memory of the animals were assessed with the Morris water maze test; the levels of malondialdehyde (MDA), hydrogen peroxide (H2O2) and superoxide dismutase (SOD) assayed by biochemical methods; and the levels of proteins related to the RAGE/NADPH pathway determined by Western blot and of the corresponding mRNAs by qPCR. After 6 months, the spatial learning and memory of the LF and HF groups had declined; their brain contents of MDA and H2O2 increased and SOD activity decreased; and the levels of the RAGE, gp91, P47, phospho-P47phox and P22 proteins and corresponding mRNAs in their brains were all elevated. Interestingly, all of these pathological changes caused by fluorosis could be attenuated by both FPS-ZM1 and EGb761. These findings indicate that the brain damage induced by fluorosis may be caused, at least in part, by enhanced RAGE/NADPH oxidase signaling and that FPS-ZM1 or EGb761 might be of clinical value in connection with the treatment of this condition.
The International journal of neuroscience
Evaluating the role of Ginkgo biloba extract in the secondary prevention of acute ischemic stroke with cerebral microbleeds by quantitative susceptibility mapping (QSM)
Article
作者: Zhang, Hui ; Wu, Yuefei ; Wu, Xin ; Lan, Wenting
BACKGROUND:
EGb 761, a standardized dry extract of Ginkgo biloba leaves, has certain anti-inflammatory and thrombotic effects and can be used to treat cerebrovascular diseases.
METHODS:
A total of 49 patients were randomly assigned to the Aspirin group (24 cases in Controlled group) and the Aspirin + Ginkgo biloba group (25 cases in Treatment group). The quantitative magnetic sensitivity and venous oxygen saturation of cerebral microbleeds were analyzed at admission, discharge, and after follow-up for 3 and 6 months.
RESULTS:
The demographic details age, gender, and admission to NIHSS were not significantly different between the two groups (p < 0.05). Quantitative susceptibility mapping (QSM) showed that the magnetic sensitivity of patients in both groups remained stable after 3 and 6 months of follow-up, while the venous oxygen saturation of the Treatment group increased. The venous oxygen saturation at 3 and 6 months of follow-up was negatively correlated with the modified mRS grade score.
CONCLUSIONS:
QSM can be used as a quantitative follow-up tool in monitoring both oxygen saturation and Magnetic susceptibility of microbleeds noninvasively in ischemic stroke patients with cerebral microbleeds. EGB combined with Aspirin can improve blood oxygen saturation in those patients and this effect is particularly significant in the long-term efficacy of secondary prevention.
2023-09-15Journal of neuroimmunology
Ginkgo biloba extract (EGb-761) confers neuroprotection against ischemic stroke by augmenting autophagic/lysosomal signaling pathway.
Article
作者: Lv, Zuyin ; Ling, Fayang ; Wu, Zhiyuan ; Sun, Jun ; Ji, Nengbo ; Yang, Licong ; Zang, Rui
Ginkgo biloba extract (EGb-761) is well-recognized to have neuroprotective properties. Meanwhile, autophagy machinery is extensively involved in the pathophysiological processes of ischemic stroke. The EGb-761 is widely used in the clinical treatment of stroke patients. However, its neuroprotective mechanisms against ischemic stroke are still not fully understood. The present study was conducted to uncover whether the pharmacological effects of EGb-761 can be executed by modulation of the autophagic/lysosomal signaling axis. A Sprague-Dawley rat model of ischemic stroke was established by middle cerebral artery occlusion (MCAO) for 90 min, followed by reperfusion. The EGb-761 was then administered to the MCAO rats once daily for a total of 7 days. Thereafter, the penumbral tissues were acquired to detect proteins involved in the autophagic/lysosomal pathway including Beclin1, LC-3, SQSTM1/p62, ubiquitin, cathepsin B, and cathepsin D by western blot and immunofluorescence, respectively. Subsequently, the therapeutic outcomes were evaluated by measuring the infarct volume, neurological deficits, and neuron survival. The results showed that the autophagic activities of Beclin1 and LC3-II in neurons were markedly promoted by 7 days of EGb-761 therapy. Meanwhile, the autophagic cargoes of insoluble p62 and ubiquitinated proteins were effectively degraded by EGb-761-augmented lysosomal activity of cathepsin B and cathepsin D. Moreover, the infarction size, neurological deficiencies, and neuron death were also substantially attenuated by EGb-761 therapy. Taken together, our study suggests that EGb-761 exerts a neuroprotective effect against ischemic stroke by promoting autophagic/lysosomal signaling in neurons at the penumbra. Thus, it might be a new therapeutic target for treating ischemic stroke.
1
项与 EGb-761 相关的新闻（医药）100 项与 EGb-761 相关的药物交易
登录后查看更多信息
研发状态
批准上市
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 耳鸣 | 临床3期 | 捷克 | 2012-06-01 | |
| 认知障碍 | 临床3期 | 法国 | - | 2010-08-11 |
| 认知功能障碍 | 临床3期 | 法国 | 2003-08-26 | |
| 复发-缓解型多发性硬化 | 临床3期 | 法国 | 2003-08-26 | |
| 缺血性卒中 | 临床3期 | 捷克 | 2003-02-01 | |
| 缺血性卒中 | 临床3期 | 波兰 | 2003-02-01 | |
| 缺血性卒中 | 临床3期 | 罗马尼亚 | 2003-02-01 | |
| 缺血性卒中 | 临床3期 | 俄罗斯 | 2003-02-01 | |
| 神经损伤 | 临床3期 | 捷克 | 2003-02-01 | |
| 神经损伤 | 临床3期 | 波兰 | 2003-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 204 | (EGb761®) | 獵範鏇窪餘憲築簾窪鏇(窪繭觸顧築觸夢簾獵願) = 糧餘願廠鏇築鑰壓築膚 製襯淵餘顧艱糧繭網鹽 (壓齋壓網範簾醖鹹艱窪, 衊衊憲衊鏇淵廠築選鏇 ~ 蓋壓選壓壓觸選顧壓簾) 更多 | - | 2018-02-19 | ||
placebo+Acetylsalicylic acid (Placebo) | 獵範鏇窪餘憲築簾窪鏇(窪繭觸顧築觸夢簾獵願) = 願繭願簾壓積製廠鏇網 製襯淵餘顧艱糧繭網鹽 (壓齋壓網範簾醖鹹艱窪, 繭廠選願餘願膚糧廠憲 ~ 鬱壓憲齋鏇鹽艱衊醖願) 更多 | ||||||
临床2期 | 49 | EGb (EGb 120 mg (Open Phase - CNE)) | 壓糧膚鑰壓鏇壓齋網遞(鬱壓鏇觸襯願網蓋蓋獵) = 鹹觸餘蓋醖鬱網壓淵鏇 齋糧壓窪壓餘糧艱築襯 (蓋窪襯醖顧蓋築壓獵艱, 觸繭簾網糧餘鏇範襯觸 ~ 選積鏇艱願願築鹹遞淵) 更多 | - | 2016-03-28 | ||
EGb (EGb 120 mg (Open Phase - MC)) | 壓糧膚鑰壓鏇壓齋網遞(鬱壓鏇觸襯願網蓋蓋獵) = 蓋艱遞衊糧齋顧構壓遞 齋糧壓窪壓餘糧艱築襯 (蓋窪襯醖顧蓋築壓獵艱, 觸齋繭築構製鑰觸鑰憲 ~ 觸蓋膚鹽簾積淵鹹範蓋) 更多 | ||||||
临床2期 | 22 | (EGb 761® 120 mg) | 鹹鏇築齋網齋製網衊餘(構餘構構鏇壓餘襯餘鹹): P-Value = 0.9133 | - | 2013-05-21 | ||
placebo (Placebo) | |||||||
临床3期 | 3,069 | (Ginkgo Biloba) | 齋餘憲糧艱願製繭築鹽(鬱鏇構壓齋壓遞遞範艱) = 艱齋醖餘獵衊壓鹽構遞 簾範製餘窪蓋觸鏇鹹選 (齋壓遞鏇夢餘顧鹹網蓋, 遞選鑰鬱餘繭築膚願築 ~ 鹽窪選積鑰願膚壓願繭) 更多 | - | 2010-09-16 | ||
Placebo (Placebo) | 齋餘憲糧艱願製繭築鹽(鬱鏇構壓齋壓遞遞範艱) = 製遞鑰窪顧顧範鏇獵衊 簾範製餘窪蓋觸鏇鹹選 (齋壓遞鏇夢餘顧鹹網蓋, 構淵網憲網製積鏇鬱醖 ~ 壓觸築願繭蓋鏇積鹽窪) 更多 | ||||||
N/A | 410 | 鑰構糧鏇窪鑰窪衊窪糧(積齋蓋繭遞廠鹹獵鏇願) = 築齋觸網窪繭顧壓觸淵 顧艱獵獵廠簾積蓋襯憲 (觸鹽遞範壓餘簾鏇製糧 ) 更多 | 积极 | 2008-07-01 | |||
Placebo | 鑰構糧鏇窪鑰窪衊窪糧(積齋蓋繭遞廠鹹獵鏇願) = 餘憲築鹹觸淵淵範鑰範 顧艱獵獵廠簾積蓋襯憲 (觸鹽遞範壓餘簾鏇製糧 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用